Nobuo Funao

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino et al. · Gut · 2016 · 420 citations · Full text

Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

Shutian Zhang, Ning Dai, Guijun Fei et al. · Gut · 2019 · 141 citations · Full text

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study

Takashi Kawai, Kazunori Oda, Nobuo Funao et al. · Gut · 2017 · 113 citations · Full text

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study

Yuji Mizokami, Kazunori Oda, Nobuo Funao et al. · Gut · 2017 · 111 citations · Full text

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

Nobuya Inagaki, Hitoshi Onouchi, Hiroki Sano et al. · The Lancet Diabetes & Endocrinology · 2013 · 54 citations

Diabetes Management, Diabetes, Pharmacology +6